Filing Flows › Procept BioRobotics (PRCT) › Q3 2026
Procept BioRobotics (PRCT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Procept BioRobotics (PRCT) reported revenue of $98.3M for the third quarter 2026 (Q3 2026), +18% from a year earlier and +4% from the quarter before. Operating margin was -27.9%, net loss $26.5M (27.0% of revenue).
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $98.3M | +4% | +18% |
| Operating profit | −$27.4M | — | — |
| Net earnings | −$26.5M | — | — |
| Operating cash flow | −$9.0M | — | — |
What changed
Revenue was $98.3M in Q3 2026, up 18% year over year and up 4% from the previous quarter.
Gross margin was 66.3%, up 1.5 points from Q3 2025. Operating costs exceeded revenue by $27.4M, an operating margin of -27.9%. Operating expenses grew 20% against revenue growth of 18%. The fastest-growing cost line was SG&A (+23%). The quarter ended with a net loss of $26.5M, narrower than the previous quarter's $26.9M loss.
Operating cash flow was −$9.0M. Non-cash charges added back $2.5M of depreciation and amortization and $15.1M of share-based compensation. Capital expenditures of $667K exceeded it, leaving free cash flow of −$9.7M.
Questions
What was Procept BioRobotics' revenue in the third quarter 2026?
Procept BioRobotics (PRCT) reported revenue of $98.3M for the third quarter 2026 (Q3 2026), +18% from a year earlier and +4% from the quarter before.
Was Procept BioRobotics profitable in the third quarter 2026?
Operating loss was $27.4M (-27.9% of revenue) and net loss $26.5M.